2022 ASH Annual Meeting Coverage—Recent Developments in Diffuse Large B-Cell Lymphoma: Insights and Application for Managed Care
1.0 Credit / Oncology
View More
CAR T-Cell Therapy Advances in Lymphoma: Implications for Managed Care
1.5 Credits / Hematology, Oncology
View More
An Article in the American Journal of Managed Care’s Evidence-Based Oncology: Navigating the Complexities of Frontline Immunotherapy in NSCLC
2 Credits / Oncology, Pulmonology/Respiratory
View More
Uncovering the Economic Burden of Chronic Cough and the Promising Role of Emerging Targeted Therapies
3.0 Credits / Pulmonology/Respiratory
View More
Evidence-Based Oncology: Discerning Novel Approaches, Recent Advances, and the Managed Care Considerations for Targeted Treatments in CLL
2.0 Credits / Hematology, Oncology
View More
Leveraging Managed Care to Optimize Patient Outcomes in Acute Myeloid Leukemia
1.5 Credits / Hematology, Oncology
View More
Discussions on Recent Data and Best Practices for Managed Care in the Treatment of nAMD and DME
1.5 Credits / Ophthalmology/Optometry
View More
Leveraging Managed Care to Increase Access to BCMA-Directed Treatment and Equitable Care in Multiple Myeloma
1.5 Credits / Hematology, Oncology
View More
Dr Chakra Chaulagain: PFS Is the "Bare Minimum," but OS Is Ideal for Choosing Between MM Therapies
Response rates are important when choosing between therapies to treat multiple myeloma (MM), but improvement overall survival (OS) is the ideal, said Chakra Chaulagain MD, FACP, hematologist/oncologist, Maroone Cancer Center of Cleveland Clinic Florida.
Alopecia Areata Impacts Patient Perception, Quality of Life
March 27th 2024Patients with alopecia areata (AA) often perceive their hair loss as more severe than dermatologists do, leading to increased emotional and social problems. This study highlights the importance of understanding patient perception for better treatment and improved quality of life.
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
FDA Issues CRLs for Odronextamab in R/R Follicular Lymphoma, R/R DLBCL
The FDA issued complete response letters (CRLs) for the biologics license application for odronextamab in relapsed/refractory (R/R) follicular lymphoma and in R/R diffuse large B-cell lymphoma (DLBCL).
New Treatments for Newly Diagnosed MM Offer a Lot of Benefit, but Key Knowledge Gaps Remain
While there is, rightfully, a lot of optimism around the latest treatments for newly diagnosed multiple myeloma, not everyone is gaining the same benefit, said Kenneth Shain, MD, PhD, of H. Lee Moffitt Cancer Center.